Compare · ICAD vs MDLN
ICAD vs MDLN
Side-by-side comparison of iCAD Inc. (ICAD) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICAD and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $52.27B, about 386.9x ICAD ($135.1M).
- MDLN has hit the wire 5 times in the past 4 weeks while ICAD has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 5 for ICAD).
- Company
- iCAD Inc.
- Medline Inc.
- Price
- $3.87+2.79%
- $38.89-2.29%
- Market cap
- $135.1M
- $52.27B
- 1M return
- -
- +6.77%
- 1Y return
- -
- -4.56%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 0
- 5
- Recent ratings
- 5
- 25
iCAD Inc.
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Latest ICAD
- MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy
- SEC Form 15-12G filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
- SEC Form EFFECT filed by iCAD Inc.
Latest MDLN
- Medline strengthens California distribution network with new 1 million-square-foot facility in Perris
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)